Nonalcoholic fatty liver disease (NAFLD, including nonalcoholic fatty liver (NAFL) and
nonalcoholic steatohepatitis (NASH)) is a high-prevalence disorder, affecting about 1 billion …

Aim This systematic review and meta-analysis was conducted to evaluate the efficacy and
safety of 4 mg saroglitazar treatment in patients with non-alcoholic fatty liver disease …

Metabolic dysfunction–associated fatty liver disease (MAFLD) prevalence and incidence is
rising globally. It is associated with metabolic comorbidities, obesity, overweight, type 2 …

BACKGROUND Non-alcoholic fatty liver disease (NAFLD) has become a prevalent cause of
chronic liver disease and ranks third among the causes of transplantation. In the United …

Metabolic-associated Fatty Liver Disease is one of the outstanding challenges in
gastroenterology. The increasing incidence of the disease is undoubtedly connected with …

Nonalcoholic fatty liver disease (NAFLD) is a global epidemic, affecting more than half of the
people living with type 2 diabetes (T2D). The relationship between NAFLD and T2D is …

Bile acids are synthesized from cholesterol in the liver. Dysregulation of bile acid
homeostasis, characterized by excessive accumulation in the liver, gallbladder and blood …

Saroglitazar (SARO), a dual peroxisome proliferator activated receptor (PPAR)-α/γ agonist,
has been used to treat metabolic diseases such as insulin resistance and diabetic …

In current work, we prepared a series of nine 4-benzyloxy-5-benzylidene-1, 3-thiazolidine-2,
4-diones using a two-step pathway. Compounds 1–9 were tested in vitro using a set of three …

The clinical implications of interconnection between genetic factors and an insulin resistant
environment that predisposes MAFLD is many fold. Potential therapeutic strategies in …